BioSpace News Archive

Deals

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex, Inc. today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock.

March 19, 2024
·
5 min read
Business

Newron Presents 2023 Financial Results and Provides 2024 Outlook

Newron Pharmaceuticals S.p.A. announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.

March 19, 2024
·
20 min read
Genetown

Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced that it has been named as a qualified contract research organization of Akoya Biosciences.

March 19, 2024
·
3 min read
Business

Repligen Appoints Maggie A. Pax to Board of Directors

Repligen Corporation announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

March 19, 2024
·
4 min read
Policy

PTC Therapeutics Provides Key Regulatory Updates

PTC Therapeutics, Inc. announced the submission of a BLA to the U.S. FDA for Upstaza™, a gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.

March 19, 2024
·
8 min read
Drug Development

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Jasper Therapeutics, Inc. today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.

March 19, 2024
·
6 min read
Business

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Theriva™ Biologics today announced that it plans to host a conference call on Monday, March 25, 2024, at 8:30 a.m. ET to discuss its financial results for the full year ended December 31, 2023 and provide a corporate update.

March 19, 2024
·
2 min read
Business

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

ClearPoint Neuro, Inc. today congratulates its partner PTC Therapeutics on completion of its BLA submission to the U.S. Food and Drug Administration (FDA) for the approval of Upstaza.

March 19, 2024
·
5 min read
Drug Development

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company’s Deltacel-01 Phase 1 clinical trial.

March 19, 2024
·
6 min read
Drug Development

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients.

March 19, 2024
·
10 min read